Compare · BDX vs SIBN
BDX vs SIBN
Side-by-side comparison of Becton Dickinson and Company (BDX) and SI-BONE Inc. (SIBN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SIBN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.58B, about 56.5x SIBN ($770.8M).
- Over the past year, BDX is down 11.6% and SIBN is up 4.5% - SIBN leads by 16.1 points.
- BDX has been more active in the news (8 items in the past 4 weeks vs 3 for SIBN).
- BDX has more recent analyst coverage (25 ratings vs 11 for SIBN).
- Company
- Becton Dickinson and Company
- SI-BONE Inc.
- Price
- $158.16-1.07%
- $17.37-1.86%
- Market cap
- $43.58B
- $770.8M
- 1M return
- +8.93%
- +12.57%
- 1Y return
- -11.60%
- +4.51%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 11
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest SIBN
- ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $52,375 worth of shares (3,134 units at $16.71), decreasing direct ownership by 1% to 277,375 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Maheshwari Anshul sold $55,627 worth of shares (3,317 units at $16.77), decreasing direct ownership by 1% to 256,560 units (SEC Form 4) to cover withholding tax
- Director Hilleman Jeryl L was granted 10,957 shares, increasing direct ownership by 33% to 43,772 units (SEC Form 4)
- Director Dunn Jeffrey W was granted 10,957 shares and sold $54,505 worth of shares (3,575 units at $15.25), increasing direct ownership by 75% to 16,057 units (SEC Form 4) to cover withholding tax
- Director Nishimura Mika was granted 10,957 shares, increasing direct ownership by 33% to 43,673 units (SEC Form 4)
- Director West Thomas A. was granted 10,957 shares, increasing direct ownership by 41% to 37,947 units (SEC Form 4)
- Director Freund John Gordon was granted 10,957 shares, increasing direct ownership by 25% to 54,258 units (SEC Form 4)
- Director Davis Timothy E Jr was granted 10,957 shares, increasing direct ownership by 17% to 76,679 units (SEC Form 4)
- SI-BONE Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits